Skip to main content

Catalyst Calendar

Scope

Mon, Sep 21, 2026

1 updates
ALKS
7:00 AM

Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

— ALKS 7290 is the First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful Improvements in ADHD Symptoms in Adults — — ALKS 7290 Was Generally Well Tolerated at All Doses Tested in Healthy Volunteers and Adults With ADHD — — Phase 2 Study of ALKS 7290 in Adults With ADHD is Enrolling,

Trial Results • Phase 1Phase 1b topline results Mon, Sep 21, 2026alkermes.com

Wed, Sep 16, 2026

1 updates
ALKS
7:00 AM

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

DUBLIN --(BUSINESS WIRE)--Sep. 16, 2026-- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company’s Board of Directors (the Board). Ms. Whitaker is a seasoned biopharmaceutical executive and experienced board director who brings

alkermes.com

Thu, Sep 10, 2026

1 updates

Mon, Aug 24, 2026

1 updates
ALKS
6:30 PM

The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

– Alixorexton Demonstrated Statistically Significant and Clinically Meaningful Improvements in Wakefulness and Cataplexy – – At All Doses Tested, Alixorexton Demonstrated Clinically Meaningful Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue, Cognition and

Trial Results • Phase 2oral presentation Mon, Aug 24, 2026alkermes.com